RxDoctor Payments DataLook up a doctor →

Salvatore Napoli, MD

Neurology · Foxboro, MANPI 1588715882

Payments from drug & device makers

$3,250,546in general payments, 2019–2025

Across 1,710 payments — averaging $1900.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$949K
  • TG Therapeutics, Inc.$419K
  • EMD Serono, Inc.$315K
  • Genentech, Inc.$197K
  • Biogen$195K
  • E.r. Squibb & Sons, L.L.C.$180K
  • plus $996K from 54 others

What the payments were for

  • Consulting fees$75,30812%
  • Speaking & faculty fees$489,59580%
  • Travel & lodging$21,0763%
  • Food & beverage$26,5954%
  • Education$3080%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis109$948,751
TG Therapeutics, Inc.78$418,651
EMD Serono, Inc.252$314,814
Genentech, Inc.30$196,673
Biogen143$195,240
E.r. Squibb & Sons, L.L.C.34$180,373
Ipsen Innovation95$153,730
Amgen(2 entities)46$134,692
Roche Products Limited146$129,427
Bristol Myers Squibb83$125,617
Sanofi61$121,999
Adamas Pharmaceuticals, Inc.20$69,404
Eisai Inc.67$47,258
Ipsen Biopharmaceuticals, Inc9$33,768
Mallinckrodt Hospital Products Inc.33$31,538
SK Life Science, Inc.50$19,878
Genentech USA, Inc.34$17,862
Mallinckrodt Enterprises LLC23$14,706
Johnson & Johnson19$13,866
Merz Pharmaceuticals, LLC2$13,500
Biohaven Pharmaceutical Holding Company Ltd.3$12,516
H. Lundbeck A S1$11,500
Ipsen Pharma SAS2$8,500
AstraZeneca(2 entities)24$7,151
ANI Pharmaceuticals, Inc.15$6,519
Merck1$4,185
Pfizer39$3,948
Eisai CO., LTD.1$3,675
Lundbeck LLC76$3,151
Greenwich Biosciences, Inc.3$2,314
AbbVie(2 entities)69$1,064
Ares Trading SA11$935
Modernatx, Inc.1$500
Life Molecular Imaging Ltd2$247
Neurocrine Biosciences, Inc.4$195
Acorda Therapeutics, Inc10$192
Biohaven Pharmaceuticals, Inc.6$182
Sunovion Pharmaceuticals Inc.9$160
Teva Pharmaceuticals USA, Inc.8$147
UCB, Inc.6$144
Alnylam Pharmaceuticals Inc.6$130
CSL Behring5$121
Lilly USA, LLC7$113
Supernus Pharmaceuticals, Inc.6$99
Kyowa Kirin, Inc.5$96
Xeris Pharmaceuticals, Inc.4$71
Strongbridge US Inc.4$69
Amneal Pharmaceuticals LLC4$59
Tanabe Pharma America, Inc.3$55
Catalyst Pharmaceuticals, Inc.3$53
Avanir Pharmaceuticals, Inc.3$52
Banner Life Sciences, LLC2$47
Acadia Pharmaceuticals Inc3$47
Argenx US, Inc.2$44
Impel Pharmaceuticals Inc.2$43
Vanda Pharmaceuticals Inc.2$41
Otsuka America Pharmaceutical, Inc.2$40
Avion Pharmaceuticals2$39
Livanova USA, Inc.2$38
Arbor Pharmaceuticals, Inc.2$38

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,250,546 in reported general payments places this provider in the 95th percentile of 761 neurology providers in Massachusetts.

See all neurology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$6,330,327
Medicare patients
430
Services billed
426,521

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab81$713,129
AubagioTeriflunomide59$648,554
OcrevusOcrelizumab12$470,511
CopaxoneGlatiramer Acetate52$288,515
TysabriNatalizumab34$283,992
AmpyraDalfampridine44$228,000
Avonex (4 Pack)Interferon Beta-1a19$151,289
Avonex Pen (4 Pack)Interferon Beta-1a18$143,988
VumerityDiroximel Fumarate14$118,432
RebifInterferon Beta-1a/Albumin11$112,968
GlatopaGlatiramer Acetate29$101,827
Dalfampridine ErDalfampridine190$89,668
VyeptiEptinezumab-Jjmr18$85,426
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5011$73,417
Teriflunomide28$61,615

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
SanofiAubagio$121,999$648,55459 claims
BiogenTysabri, Avonex (4 Pack), Vumerity$195,240$553,71367 claims
Genentech, Inc.Ocrevus$196,673$470,51112 claims
Teva Pharmaceuticals USA, Inc.Copaxone$147$288,51552 claims
Acorda Therapeutics, IncAmpyra$192$228,00044 claims
EMD Serono, Inc.Rebif$314,814$112,96811 claims
Lundbeck LLCVyepti$3,151$85,42618 claims
AbbVieBotox, Qulipta$1,064$37,30032 claims
PfizerNurtec Odt$3,948$35,80522 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 761 neurology providers in Massachusetts.

Other neurology in Foxboro

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →